These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of heroin-dependent persons with antagonists: current status. Renault PF. NIDA Res Monogr; 1981 Sep; 28():11-22. PubMed ID: 6791000 [Abstract] [Full Text] [Related]
3. Addiction and the community. (Narcotic substitution therapy). Taylor WJ, Chambers CD, Bowling CE. Int J Clin Pharmacol; 1972 Apr; 6(1):28-39. PubMed ID: 4625924 [No Abstract] [Full Text] [Related]
4. Cyclazocine in the treatment of narcotic addiction. Jaffe JH. Curr Psychiatr Ther; 1967 Apr; 7():147-56. PubMed ID: 4860298 [No Abstract] [Full Text] [Related]
5. Historical perspective on the chemistry and development of naltrexone. Archer S. NIDA Res Monogr; 1981 Apr; 28():3-10. PubMed ID: 6791011 [Abstract] [Full Text] [Related]
6. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818 [Abstract] [Full Text] [Related]
7. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Chen TJ, Blum K, Payte JT, Schoolfield J, Hopper D, Stanford M, Braverman ER. Med Hypotheses; 2004 Dec; 63(3):538-48. PubMed ID: 15288384 [Abstract] [Full Text] [Related]
10. [Limited role of naltrexone in the treatment of opiate addiction]. van Brussel GH. Ned Tijdschr Geneeskd; 2001 Jul 28; 145(30):1452-6. PubMed ID: 11503313 [Abstract] [Full Text] [Related]
11. Opiate physical dependence and N-methyl-D-aspartate receptors. Noda Y, Nabeshima T. Eur J Pharmacol; 2004 Oct 01; 500(1-3):121-8. PubMed ID: 15464026 [Abstract] [Full Text] [Related]
16. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Foster J, Brewer C, Steele T. Addict Biol; 2003 Jun 01; 8(2):211-7. PubMed ID: 12850780 [Abstract] [Full Text] [Related]
17. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy]. Roozen HG, Deden AL, Kerkhof AJ, Vorsteveld JP, van den Brink W. Ned Tijdschr Geneeskd; 1997 Dec 06; 141(49):2377-80. PubMed ID: 9554156 [Abstract] [Full Text] [Related]
18. Use of the novel irreversible opiate antagonist, beta-chlornaltrexamine, in the estimation of the normorphine affinity constant in naive and morphine tolerant guinea-pig ilea. Porreca F, Burks TF. Proc West Pharmacol Soc; 1983 Dec 06; 26():295-7. PubMed ID: 6684293 [No Abstract] [Full Text] [Related]
19. Certain theoretical and practical considerations involved in evaluating the overall abuse potential of opiate agonists and antagonists. Fraser HF. Adv Biochem Psychopharmacol; 1973 Dec 06; 8(0):439-53. PubMed ID: 4604198 [No Abstract] [Full Text] [Related]
20. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Sadée W, Wang D, Bilsky EJ. Life Sci; 2005 Feb 11; 76(13):1427-37. PubMed ID: 15680308 [Abstract] [Full Text] [Related] Page: [Next] [New Search]